EI
MACK

EAM Investors’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

EAM Investors’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-44,537
Closed -$4.33M – 394
2015
Q2 		$4.33M Sell
44,537
-2,746
-6% -$261K 0.51% 51
2015
Q1 		$4.42M Sell
47,283
-5,112
-10% -$435K 0.51% 36
2014
Q4 		$4.66M Buy
52,395
+17,709
+51% +$1.29M 0.65% 14
2014
Q3 		$2.4M Buy
34,686
+19,648
+131% +$1.05M 0.49% 47
2014
Q2 		$863K Buy
+15,038
New +$764K 0.16% 304

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
LIM
Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

EAM Investors's MACK Position: Q3 2015 in Review

EAM Investors sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2015, closing a stake of 44,537 shares — an estimated $4.33M sold.

EAM Investors first reported a position in MACK in Q2 2014 and held it in 5 quarters. The position peaked at $4.66M in Q4 2014. 135 funds tracked by Wall St. Rank hold MACK as of Q3 2015.

  • EAM Investors reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2015 after selling out during the quarter.
  • EAM Investors sold 44,537 Merrimack Pharmaceuticals, Inc. shares in Q3 2015, an estimated $4.33M.
  • EAM Investors first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2014 and held it in 5 quarters.
  • EAM Investors's Merrimack Pharmaceuticals, Inc. position peaked at $4.66M in Q4 2014.
  • 135 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2015.

Based on EAM Investors's 13F filing for Q3 2015, filed 6 Nov 2015.